Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials.

Mantovani A, Byrne CD, Scorletti E, Mantzoros CS, Targher G

Diabetes & metabolism7 Jan 2020Cited by 99 (Europe PMC)

PMID31923578DOI10.1016/j.diabet.2019.12.007PepBankPUB-31923578

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

1 result from studies that gave the peptide. 1 result from people.

01HumanSystematic reviewEfficacy outcome
In a systematic review of randomized trials in people with NAFLD, liraglutide showed an improvement of histologic features of NAFLD.
In plain wordsIn a review of trials in people with fatty liver disease, liraglutide improved liver tissue findings.
Peptide
Liraglutide
Outcome
IncreaseHistologic features of NAFLD
Study
n: not reported in source
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated
Source sentences
Summary
only glitazones (especially pioglitazone) and liraglutide showed an improvement of histologic features of NAFLD
1 context sentence(design, population, supporting numbers)
Summary · context
We included 29 RCTs involving a total of 2,617 individuals (∼45% had T2DM) that have used metformin (n=6 studies), glitazones (n=8 studies), glucagon-like peptide-1 receptor agonists (n=6 studies), dipeptidyl peptidase-4 inhibitors (n=4 studies) or sodium-glucose cotransporter-2 inhibitors (n=7 studies) to treat NAFLD.
Report a problemFND-3192357801

Studies that did not test the peptide alone1

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

02HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In a systematic review of randomized trials in people with NAFLD, most anti-hyperglycaemic drugs, as a pooled group, improved serum liver enzyme levels.
In plain wordsIn a review of trials in people with fatty liver disease, most diabetes drugs as a group improved liver enzyme levels.
Peptide
Liraglutide
Outcome
DecreaseSerum liver enzyme levels (pooled anti-hyperglycaemic drugs)
Study
n: not reported in source
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
Although most anti-hyperglycaemic drugs improved serum liver enzyme levels
1 context sentence(design, population, supporting numbers)
Summary · context
We included 29 RCTs involving a total of 2,617 individuals (∼45% had T2DM) that have used metformin (n=6 studies), glitazones (n=8 studies), glucagon-like peptide-1 receptor agonists (n=6 studies), dipeptidyl peptidase-4 inhibitors (n=4 studies) or sodium-glucose cotransporter-2 inhibitors (n=7 studies) to treat NAFLD.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3192357802

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.